Difference between revisions of "deLemus"
Jump to navigation
Jump to search
| Line 19: | Line 19: | ||
|14 | |14 | ||
|A novel phosphorylation site in SARS-CoV-2 nucleocapsid regulates its RNA-binding capacity and phase separation in host cells | |A novel phosphorylation site in SARS-CoV-2 nucleocapsid regulates its RNA-binding capacity and phase separation in host cells | ||
| − | | | + | |https://academic.oup.com/jmcb/advance-article/doi/10.1093/jmcb/mjac003/6510820?login=false#/ |
|0 | |0 | ||
|- | |- | ||
|34 | |34 | ||
|Airborne transmission of respiratory viruses | |Airborne transmission of respiratory viruses | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abd9149/ |
|0 | |0 | ||
|- | |- | ||
|36 | |36 | ||
|SARS-CoV-2 infection in free-ranging white-tailed deer | |SARS-CoV-2 infection in free-ranging white-tailed deer | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-04353-x?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|0 | |0 | ||
|- | |- | ||
|41 | |41 | ||
|Do childhood colds help the body respond to COVID? | |Do childhood colds help the body respond to COVID? | ||
| − | | | + | |https://www.nature.com/articles/d41586-021-03087-0?utm_source=twt_nat&utm_medium=social&utm_campaign=nature/ |
|0 | |0 | ||
|- | |- | ||
|42 | |42 | ||
|Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort | |Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort | ||
| − | | | + | |https://www.science.org/doi/10.1126/scitranslmed.abj7521?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|0 | |0 | ||
|- | |- | ||
|43 | |43 | ||
|Immune memory from SARS-CoV-2 infection in hamsters provides variant-independent protection but still allows virus transmission | |Immune memory from SARS-CoV-2 infection in hamsters provides variant-independent protection but still allows virus transmission | ||
| − | | | + | |https://www.science.org/doi/10.1126/sciimmunol.abm3131?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|0 | |0 | ||
|- | |- | ||
|47 | |47 | ||
|Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses | |Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses | ||
| − | | | + | |https://www.science.org/doi/10.1126/sciimmunol.abl5842?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|0 | |0 | ||
|- | |- | ||
|59 | |59 | ||
|Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection | |Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection | ||
| − | | | + | |https://www.nature.com/articles/s41591-021-01540-1?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_NRJournals/ |
|0 | |0 | ||
|- | |- | ||
|65 | |65 | ||
|Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates | |Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates | ||
| − | | | + | |https://www.science.org/doi/full/10.1126/science.abj0299?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|0 | |0 | ||
|- | |- | ||
|66 | |66 | ||
|How do vaccinated people spread Delta? What the science says | |How do vaccinated people spread Delta? What the science says | ||
| − | | | + | |https://www.nature.com/articles/d41586-021-02187-1?utm_source=twt_nat&utm_medium=social&utm_campaign=nature/ |
|0 | |0 | ||
|- | |- | ||
|72 | |72 | ||
|Boosting stem cell immunity to viruses | |Boosting stem cell immunity to viruses | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abj5673/ |
|0 | |0 | ||
|- | |- | ||
|73 | |73 | ||
|Targeting aging cells improves survival | |Targeting aging cells improves survival | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abi4474/ |
|0 | |0 | ||
|- | |- | ||
|74 | |74 | ||
|After the pandemic: perspectives on the future trajectory of COVID-19 | |After the pandemic: perspectives on the future trajectory of COVID-19 | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-03792-w?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|2 | |2 | ||
|- | |- | ||
|87 | |87 | ||
|Hybrid immunity | |Hybrid immunity | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abj2258/ |
|0 | |0 | ||
|- | |- | ||
|93 | |93 | ||
|How your DNA may affect whether you get COVID-19 or become gravely ill | |How your DNA may affect whether you get COVID-19 or become gravely ill | ||
| − | | | + | |https://www.sciencenews.org/article/coronavirus-covid-how-dna-genetic-risk-infection-severe-illness/ |
|0 | |0 | ||
|- | |- | ||
|95 | |95 | ||
|Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection | |Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-03696-9?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|0 | |0 | ||
|- | |- | ||
|96 | |96 | ||
|How were the first treatments for COVID identified? | |How were the first treatments for COVID identified? | ||
| − | | | + | |https://www.compoundchem.com/2021/06/16/recovery-trial// |
|0 | |0 | ||
|- | |- | ||
|100 | |100 | ||
|Antibody sugars are bittersweet | |Antibody sugars are bittersweet | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abj0435/ |
|0 | |0 | ||
|- | |- | ||
|101 | |101 | ||
|CRISPR diagnostics | |CRISPR diagnostics | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abi9335/ |
|0 | |0 | ||
|- | |- | ||
|104 | |104 | ||
|Complement control for COVID-19 | |Complement control for COVID-19 | ||
| − | | | + | |https://www.science.org/doi/10.1126/sciimmunol.abj1014/ |
|0 | |0 | ||
|- | |- | ||
|109 | |109 | ||
|Estimating infectiousness throughout SARS-CoV-2 infection course | |Estimating infectiousness throughout SARS-CoV-2 infection course | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abi5273/ |
|0 | |0 | ||
|- | |- | ||
|115 | |115 | ||
|Face masks effectively limit the probability of SARS-CoV-2 transmission | |Face masks effectively limit the probability of SARS-CoV-2 transmission | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abg6296/ |
|0 | |0 | ||
|- | |- | ||
|126 | |126 | ||
|How COVID broke the evidence pipeline | |How COVID broke the evidence pipeline | ||
| − | | | + | |https://www.nature.com/articles/d41586-021-01246-x?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|0 | |0 | ||
|- | |- | ||
|131 | |131 | ||
|It’s time to consider a patent reprieve for COVID vaccines | |It’s time to consider a patent reprieve for COVID vaccines | ||
| − | | | + | |https://www.nature.com/articles/d41586-021-00863-w?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|0 | |0 | ||
|- | |- | ||
|132 | |132 | ||
|SARS-CoV-2 transmission without symptoms | |SARS-CoV-2 transmission without symptoms | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abf9569/ |
|0 | |0 | ||
|- | |- | ||
|135 | |135 | ||
|Five reasons why COVID herd immunity is probably impossible | |Five reasons why COVID herd immunity is probably impossible | ||
| − | | | + | |https://www.nature.com/articles/d41586-021-00728-2?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|0 | |0 | ||
|- | |- | ||
|137 | |137 | ||
|Rare COVID reactions might hold key to variant-proof vaccines | |Rare COVID reactions might hold key to variant-proof vaccines | ||
| − | | | + | |https://www.nature.com/articles/d41586-021-00722-8?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|0 | |0 | ||
|- | |- | ||
|138 | |138 | ||
|Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 | |Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-03426-1?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|0 | |0 | ||
|- | |- | ||
|139 | |139 | ||
|Cell Press Coronavirus Resource Hub | |Cell Press Coronavirus Resource Hub | ||
| − | | | + | |https://www.cell.com/COVID-19/ |
|0 | |0 | ||
|- | |- | ||
|140 | |140 | ||
|Nexstrain SARS-CoV-2 resources | |Nexstrain SARS-CoV-2 resources | ||
| − | | | + | |https://nextstrain.org/sars-cov-2// |
|0 | |0 | ||
|- | |- | ||
|141 | |141 | ||
|CoVariants | |CoVariants | ||
| − | | | + | |https://covariants.org// |
|0 | |0 | ||
|- | |- | ||
|142 | |142 | ||
|The GISAID Database | |The GISAID Database | ||
| − | | | + | |https://www.gisaid.org// |
|0 | |0 | ||
|- | |- | ||
|143 | |143 | ||
|UniProt (Data Retrieving) | |UniProt (Data Retrieving) | ||
| − | | | + | |https://www.uniprot.org/uploadlists// |
|0 | |0 | ||
|- | |- | ||
|161 | |161 | ||
|Multiple Sequence Alignment | |Multiple Sequence Alignment | ||
| − | | | + | |https://www.ebi.ac.uk/Tools/msa/clustalo// |
|0 | |0 | ||
|- | |- | ||
|6 | |6 | ||
|InterPro (List of Protein Family) | |InterPro (List of Protein Family) | ||
| − | | | + | |https://www.ebi.ac.uk/interpro// |
|0 | |0 | ||
|- | |- | ||
|7 | |7 | ||
|More evidence suggests COVID-19 was in the US by Christmas 2019 | |More evidence suggests COVID-19 was in the US by Christmas 2019 | ||
| − | | | + | |https://apnews.com/article/more-evidence-covid-in-US-by-Christmas-2019-11346afc5e18eee81ebcf35d9e6caee2/ |
|0 | |0 | ||
|- | |- | ||
|9 | |9 | ||
|A COVID Vaccine for All | |A COVID Vaccine for All | ||
| − | | | + | |https://www.scientificamerican.com/article/a-covid-vaccine-for-all// |
|1 | |1 | ||
|- | |- | ||
|10 | |10 | ||
|Single-cell immunology of SARS-CoV-2 infection | |Single-cell immunology of SARS-CoV-2 infection | ||
| − | | | + | |https://www.nature.com/articles/s41587-021-01131-y?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_NRJournals/ |
|1 | |1 | ||
|- | |- | ||
|11 | |11 | ||
|Innate immunological pathways in COVID-19 pathogenesis | |Innate immunological pathways in COVID-19 pathogenesis | ||
| − | | | + | |https://www.science.org/doi/10.1126/sciimmunol.abm5505?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|1 | |1 | ||
|- | |- | ||
|15 | |15 | ||
|Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity | |Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity | ||
| − | | | + | |https://www.science.org/doi/10.1126/scitranslmed.abm7853?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|1 | |1 | ||
|- | |- | ||
|22 | |22 | ||
|COVID-19 vaccine side effects: The positives about feeling bad | |COVID-19 vaccine side effects: The positives about feeling bad | ||
| − | | | + | |https://www.science.org/doi/10.1126/sciimmunol.abj9256?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|1 | |1 | ||
|- | |- | ||
|24 | |24 | ||
|COVID-19 vaccine breakthrough infections | |COVID-19 vaccine breakthrough infections | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abl8487?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|1 | |1 | ||
|- | |- | ||
|25 | |25 | ||
|B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes | |B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes | ||
| − | | | + | |https://www.biorxiv.org/content/10.1101/2021.12.07.470392v1/ |
|1 | |1 | ||
|- | |- | ||
|26 | |26 | ||
|Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses — are we our own worst enemy? | |Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses — are we our own worst enemy? | ||
| − | | | + | |https://www.nature.com/articles/s41577-021-00656-2?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_NRJournals/ |
|1 | |1 | ||
|- | |- | ||
|32 | |32 | ||
|Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals | |Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2 experienced individuals | ||
| − | | | + | |https://www.science.org/doi/10.1126/scitranslmed.abi8961?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|1 | |1 | ||
|- | |- | ||
|33 | |33 | ||
|mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern | |mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abm0829?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|1 | |1 | ||
|- | |- | ||
|39 | |39 | ||
|Amilorides inhibit SARS-CoV-2 replication in vitro by targeting RNA structures | |Amilorides inhibit SARS-CoV-2 replication in vitro by targeting RNA structures | ||
| − | | | + | |https://www.science.org/doi/10.1126/sciadv.abl6096/ |
|1 | |1 | ||
|- | |- | ||
|44 | |44 | ||
|Allelic variation in class I HLA determines CD8+ T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2 | |Allelic variation in class I HLA determines CD8+ T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2 | ||
| − | | | + | |https://www.science.org/doi/10.1126/sciimmunol.abk3070?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|1 | |1 | ||
|- | |- | ||
|48 | |48 | ||
|A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice | |A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice | ||
| − | | | + | |https://www.science.org/doi/10.1126/scitranslmed.abj7125?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|1 | |1 | ||
|- | |- | ||
|50 | |50 | ||
|Scent of a vaccine | |Scent of a vaccine | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abg9857?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|1 | |1 | ||
|- | |- | ||
|52 | |52 | ||
|A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19 | |A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19 | ||
| − | | | + | |https://www.nature.com/articles/s41467-021-25480-z/ |
|1 | |1 | ||
|- | |- | ||
|53 | |53 | ||
|High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape | |High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-04005-0?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|1 | |1 | ||
|- | |- | ||
|54 | |54 | ||
|Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern | |Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern | ||
| − | | | + | |https://www.science.org/doi/10.1126/scitranslmed.abj5413?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|1 | |1 | ||
|- | |- | ||
|58 | |58 | ||
|Broad betacoronavirus neutralization by a stem helix–specific human antibody | |Broad betacoronavirus neutralization by a stem helix–specific human antibody | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abj3321?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|1 | |1 | ||
|- | |- | ||
|61 | |61 | ||
|Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice | |Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abi4506?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|1 | |1 | ||
|- | |- | ||
|62 | |62 | ||
|Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants | |Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abh1766/ |
|1 | |1 | ||
|- | |- | ||
|63 | |63 | ||
|Cross-reactive antibodies against human coronaviruses and the animal coronavirome suggest diagnostics for future zoonotic spillovers | |Cross-reactive antibodies against human coronaviruses and the animal coronavirome suggest diagnostics for future zoonotic spillovers | ||
| − | | | + | |https://www.science.org/doi/10.1126/sciimmunol.abe9950/ |
|1 | |1 | ||
|- | |- | ||
|64 | |64 | ||
|Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants | |Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants | ||
| − | | | + | |https://www.nature.com/articles/s41467-021-24909-9?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_NRJournals/ |
|1 | |1 | ||
|- | |- | ||
|67 | |67 | ||
|Broad sarbecovirus neutralization by a human monoclonal antibody | |Broad sarbecovirus neutralization by a human monoclonal antibody | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-03817-4?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|1 | |1 | ||
|- | |- | ||
|69 | |69 | ||
|Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine | |Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-03841-4?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|1 | |1 | ||
|- | |- | ||
|70 | |70 | ||
|Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination | |Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination | ||
| − | | | + | |https://www.nature.com/articles/s41591-021-01449-9?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_NRJournals/ |
|1 | |1 | ||
|- | |- | ||
|71 | |71 | ||
|Systems vaccinology of the BNT162b2 mRNA vaccine in humans | |Systems vaccinology of the BNT162b2 mRNA vaccine in humans | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-03791-x?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|1 | |1 | ||
|- | |- | ||
|75 | |75 | ||
|A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters | |A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters | ||
| − | | | + | |https://www.science.org/doi/10.1126/scitranslmed.abg1143/ |
|1 | |1 | ||
|- | |- | ||
|76 | |76 | ||
|Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2 | |Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2 | ||
| − | | | + | |https://www.science.org/doi/full/10.1126/science.abg5827/ |
|1 | |1 | ||
|- | |- | ||
|83 | |83 | ||
|Engineered single-domain antibodies tackle COVID variants | |Engineered single-domain antibodies tackle COVID variants | ||
| − | | | + | |https://www.nature.com/articles/d41586-021-01721-5?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|1 | |1 | ||
|- | |- | ||
|84 | |84 | ||
|CD8+ T cells specific for conserved coronavirus epitopes correlate with milder disease in patients with COVID-19 | |CD8+ T cells specific for conserved coronavirus epitopes correlate with milder disease in patients with COVID-19 | ||
| − | | | + | |https://www.science.org/doi/10.1126/sciimmunol.abg5669/ |
|1 | |1 | ||
|- | |- | ||
|89 | |89 | ||
|Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals | |Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals | ||
| − | | | + | |https://www.nature.com/articles/s41591-021-01413-7?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_NRJournals/ |
|1 | |1 | ||
|- | |- | ||
|92 | |92 | ||
|Artificial Proteins Never Seen in the Natural World Are Becoming New COVID Vaccines and Medicines | |Artificial Proteins Never Seen in the Natural World Are Becoming New COVID Vaccines and Medicines | ||
| − | | | + | |https://www.scientificamerican.com/article/artificial-proteins-never-seen-in-the-natural-world-are-becoming-new-covid-vaccines-and-medicines// |
|1 | |1 | ||
|- | |- | ||
|94 | |94 | ||
|Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2 | |Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2 | ||
| − | | | + | |https://www.science.org/doi/full/10.1126/science.abi4708/ |
|1 | |1 | ||
|- | |- | ||
|98 | |98 | ||
|Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom | |Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom | ||
| − | | | + | |https://www.nature.com/articles/s41591-021-01410-w?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_NRJournals/ |
|1 | |1 | ||
|- | |- | ||
|103 | |103 | ||
|Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans | |Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-03681-2?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|1 | |1 | ||
|- | |- | ||
|106 | |106 | ||
|BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans | |BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-03653-6?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|1 | |1 | ||
|- | |- | ||
|108 | |108 | ||
|SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients | |SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients | ||
| − | | | + | |https://www.science.org/doi/10.1126/sciimmunol.abj1750/ |
|1 | |1 | ||
|- | |- | ||
|112 | |112 | ||
|Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues | |Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abf6648/ |
|1 | |1 | ||
|- | |- | ||
|114 | |114 | ||
|A network analysis of COVID-19 mRNA vaccine patents | |A network analysis of COVID-19 mRNA vaccine patents | ||
| − | | | + | |https://www.nature.com/articles/s41587-021-00912-9?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_NRJournals/ |
|1 | |1 | ||
|- | |- | ||
|117 | |117 | ||
|High titers and low fucosylation of early human anti–SARS-CoV-2 IgG promote inflammation by alveolar macrophages | |High titers and low fucosylation of early human anti–SARS-CoV-2 IgG promote inflammation by alveolar macrophages | ||
| − | | | + | |https://www.science.org/doi/10.1126/scitranslmed.abf8654/ |
|1 | |1 | ||
|- | |- | ||
|119 | |119 | ||
|COVID-19–related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters | |COVID-19–related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters | ||
| − | | | + | |https://www.science.org/doi/10.1126/scitranslmed.abf8396/ |
|1 | |1 | ||
|- | |- | ||
|121 | |121 | ||
|How Pfizer Makes Its Covid-19 Vaccine | |How Pfizer Makes Its Covid-19 Vaccine | ||
| − | | | + | |https://www.nytimes.com/interactive/2021/health/pfizer-coronavirus-vaccine.html?smid=tw-share/ |
|1 | |1 | ||
|- | |- | ||
|123 | |123 | ||
|A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice | |A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice | ||
| − | | | + | |https://www.biorxiv.org/content/10.1101/2021.04.27.441655v1/ |
|1 | |1 | ||
|- | |- | ||
|124 | |124 | ||
|Adjuvanting a subunit COVID-19 vaccine to induce protective immunity | |Adjuvanting a subunit COVID-19 vaccine to induce protective immunity | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-03530-2/ |
|1 | |1 | ||
|- | |- | ||
|129 | |129 | ||
|The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD | |The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD | ||
| − | | | + | |https://www.biorxiv.org/content/10.1101/2021.04.14.439844v1/ |
|1 | |1 | ||
|- | |- | ||
|136 | |136 | ||
|The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates | |The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates | ||
| − | | | + | |https://www.science.org/doi/10.1126/scitranslmed.abf1906/ |
|1 | |1 | ||
|- | |- | ||
|145 | |145 | ||
|Immunity to SARS-CoV-2 variants of concern | |Immunity to SARS-CoV-2 variants of concern | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abg7404/ |
|1 | |1 | ||
|- | |- | ||
|146 | |146 | ||
|Lilly COVID-19 Antibody Combination Shows 87% Risk Reduction in Phase III Trial | |Lilly COVID-19 Antibody Combination Shows 87% Risk Reduction in Phase III Trial | ||
| − | | | + | |https://www.genengnews.com/news/lilly-covid-19-antibody-combination-shows-87-risk-reduction-in-phase-iii-trial// |
|1 | |1 | ||
|- | |- | ||
|148 | |148 | ||
|Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2 | |Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2 | ||
| − | | | + | |https://www.ijbs.com/v16p1718.htm/ |
|1 | |1 | ||
|- | |- | ||
|149 | |149 | ||
|Targeting the SARS-CoV-2-spike protein: from antibodies to miniproteins and peptides | |Targeting the SARS-CoV-2-spike protein: from antibodies to miniproteins and peptides | ||
| − | | | + | |https://pubs.rsc.org/en/content/articlelanding/2021/md/d0md00385a#!divAbstract/ |
|1 | |1 | ||
|- | |- | ||
|151 | |151 | ||
|SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma | |SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma | ||
| − | | | + | |https://www.nature.com/articles/s41591-021-01285-x/ |
|1 | |1 | ||
|- | |- | ||
|153 | |153 | ||
|A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein | |A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein | ||
| − | | | + | |https://www.nature.com/articles/s41467-020-20602-5/ |
|1 | |1 | ||
|- | |- | ||
|2 | |2 | ||
|Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 | |Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 | ||
| − | | | + | |https://www.nature.com/articles/s41591-021-01325-6/ |
|1 | |1 | ||
|- | |- | ||
|12 | |12 | ||
|The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in non-human primates | |The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in non-human primates | ||
| − | | | + | |https://stm.sciencemag.org/content/early/2021/04/05/scitranslmed.abf1906.full/ |
|1 | |1 | ||
|- | |- | ||
|35 | |35 | ||
|Evolutionary trajectory of SARS-CoV-2 and emerging variants | |Evolutionary trajectory of SARS-CoV-2 and emerging variants | ||
| − | | | + | |https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01633-w/ |
|2 | |2 | ||
|- | |- | ||
|45 | |45 | ||
|Dynamic Expedition of Leading Mutations in SARS-CoV-2 Spike Glycoproteins | |Dynamic Expedition of Leading Mutations in SARS-CoV-2 Spike Glycoproteins | ||
| − | | | + | |https://www.biorxiv.org/content/10.1101/2021.12.29.474427v1/ |
|2 | |2 | ||
|- | |- | ||
|46 | |46 | ||
|Mapping the proteo-genomic convergence of human diseases | |Mapping the proteo-genomic convergence of human diseases | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abj1541?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|2 | |2 | ||
|- | |- | ||
|49 | |49 | ||
|From Alpha to Epsilon: Consortium study illuminates surfaces of Spike most resistant to antibody escape | |From Alpha to Epsilon: Consortium study illuminates surfaces of Spike most resistant to antibody escape | ||
| − | | | + | |https://www.lji.org/news-events/news/post/from-alpha-to-epsilon-consortium-study-illuminates-surfaces-of-spike-most-resistant-to-antibody-escape// |
|2 | |2 | ||
|- | |- | ||
|91 | |91 | ||
|Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study | |Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abh2315#.YVFR4Ob9en8.twitter/ |
|2 | |2 | ||
|- | |- | ||
|99 | |99 | ||
|The biological and clinical significance of emerging SARS-CoV-2 variants | |The biological and clinical significance of emerging SARS-CoV-2 variants | ||
| − | | | + | |https://www.nature.com/articles/s41576-021-00408-x?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_NRJournals/ |
|2 | |2 | ||
|- | |- | ||
|152 | |152 | ||
|Evolution of a virus-like architecture and packaging mechanism in a repurposed bacterial protein | |Evolution of a virus-like architecture and packaging mechanism in a repurposed bacterial protein | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abg2822/ |
|2 | |2 | ||
|- | |- | ||
|156 | |156 | ||
|Spike mutation T403R allows bat coronavirus RaTG13 to use human ACE2 | |Spike mutation T403R allows bat coronavirus RaTG13 to use human ACE2 | ||
| − | | | + | |https://www.biorxiv.org/content/10.1101/2021.05.31.446386v1/ |
|2 | |2 | ||
|- | |- | ||
|16 | |16 | ||
|Evolution of antibody immunity to SARS-CoV-2 | |Evolution of antibody immunity to SARS-CoV-2 | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-03207-w/ |
|2 | |2 | ||
|- | |- | ||
|17 | |17 | ||
|Evolution of antibody immunity to SARS-CoV2 | |Evolution of antibody immunity to SARS-CoV2 | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-03207-w/ |
|2 | |2 | ||
|- | |- | ||
|19 | |19 | ||
|Innovative X-ray imaging shows COVID-19 can cause vascular damage to the heart | |Innovative X-ray imaging shows COVID-19 can cause vascular damage to the heart | ||
| − | | | + | |https://medicalxpress.com/news/2021-12-x-ray-imaging-covid-vascular-heart.html/ |
|3 | |3 | ||
|- | |- | ||
|21 | |21 | ||
|Bacteriophage self-counting in the presence of viral replication | |Bacteriophage self-counting in the presence of viral replication | ||
| − | | | + | |https://www.pnas.org/content/118/51/e2104163118/ |
|3 | |3 | ||
|- | |- | ||
|37 | |37 | ||
|Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding | |Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding | ||
| − | | | + | |https://www.cell.com/cell-reports/fulltext/S2211-1247(21)01652-1#.YbBFgwgnRMI.twitter/ |
|3 | |3 | ||
|- | |- | ||
|40 | |40 | ||
|Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain | |Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abl6251?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|3 | |3 | ||
|- | |- | ||
|51 | |51 | ||
|Ensemble cryo-electron microscopy reveals conformational states of the nsp13 helicase in the SARS-CoV-2 helicase replication-transcription complex | |Ensemble cryo-electron microscopy reveals conformational states of the nsp13 helicase in the SARS-CoV-2 helicase replication-transcription complex | ||
| − | | | + | |https://www.biorxiv.org/content/10.1101/2021.11.10.468168v1/ |
|3 | |3 | ||
|- | |- | ||
|56 | |56 | ||
|Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant | |Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abl9463?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|3 | |3 | ||
|- | |- | ||
|57 | |57 | ||
|Structural basis of mismatch recognition by a SARS-CoV-2 proofreading enzyme | |Structural basis of mismatch recognition by a SARS-CoV-2 proofreading enzyme | ||
| − | | | + | |https://www.science.org/doi/full/10.1126/science.abi9310?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|3 | |3 | ||
|- | |- | ||
|78 | |78 | ||
|Water-Triggered, Irreversible Conformational Change of SARS-CoV-2 Main Protease on Passing from the Solid State to Aqueous Solution | |Water-Triggered, Irreversible Conformational Change of SARS-CoV-2 Main Protease on Passing from the Solid State to Aqueous Solution | ||
| − | | | + | |https://pubs.acs.org/doi/10.1021/jacs.1c05301/ |
|3 | |3 | ||
|- | |- | ||
|79 | |79 | ||
|A glycan gate controls opening of the SARS-CoV-2 spike protein | |A glycan gate controls opening of the SARS-CoV-2 spike protein | ||
| − | | | + | |https://www.nature.com/articles/s41557-021-00758-3?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_NRJournals/ |
|3 | |3 | ||
|- | |- | ||
|80 | |80 | ||
|The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells | |The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells | ||
| − | | | + | |https://www.nature.com/articles/s41467-021-24342-y?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_NRJournals/ |
|3 | |3 | ||
|- | |- | ||
|81 | |81 | ||
|Identification of SARS-CoV-2–induced pathways reveals drug repurposing strategies | |Identification of SARS-CoV-2–induced pathways reveals drug repurposing strategies | ||
| − | | | + | |https://www.science.org/doi/10.1126/sciadv.abh3032/ |
|3 | |3 | ||
|- | |- | ||
|82 | |82 | ||
|Mn2+ coordinates Cap-0-RNA to align substrates for efficient 2′-O-methyl transfer by SARS-CoV-2 nsp16 | |Mn2+ coordinates Cap-0-RNA to align substrates for efficient 2′-O-methyl transfer by SARS-CoV-2 nsp16 | ||
| − | | | + | |https://www.science.org/doi/10.1126/scisignal.abh2071/ |
|3 | |3 | ||
|- | |- | ||
|85 | |85 | ||
|A potential interaction between the SARS-CoV-2 spike protein and nicotinic acetylcholine receptors | |A potential interaction between the SARS-CoV-2 spike protein and nicotinic acetylcholine receptors | ||
| − | | | + | |https://www.cell.com/biophysj/fulltext/S0006-3495(21)00146-6/ |
|3 | |3 | ||
|- | |- | ||
|86 | |86 | ||
|Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genome | |Structural basis of ribosomal frameshifting during translation of the SARS-CoV-2 RNA genome | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abf3546/ |
|3 | |3 | ||
|- | |- | ||
|88 | |88 | ||
|Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques | |Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-03732-8?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|3 | |3 | ||
|- | |- | ||
|90 | |90 | ||
|Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs | |Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs | ||
| − | | | + | |https://www.nature.com/articles/s41594-021-00619-0?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_NRJournals/ |
|3 | |3 | ||
|- | |- | ||
|102 | |102 | ||
|A multi-omics investigation of the composition and function of extracellular vesicles along the temporal trajectory of COVID-19 | |A multi-omics investigation of the composition and function of extracellular vesicles along the temporal trajectory of COVID-19 | ||
| − | | | + | |https://www.nature.com/articles/s42255-021-00425-4?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_NRJournals/ |
|3 | |3 | ||
|- | |- | ||
|105 | |105 | ||
|Improving SARS-CoV-2 structures: Peer review by early coordinate release | |Improving SARS-CoV-2 structures: Peer review by early coordinate release | ||
| − | | | + | |https://www.cell.com/biophysj/fulltext/S0006-3495(21)00046-1/ |
|3 | |3 | ||
|- | |- | ||
|107 | |107 | ||
|Cooperative multivalent receptor binding promotes exposure of the SARS-CoV-2 fusion machinery core | |Cooperative multivalent receptor binding promotes exposure of the SARS-CoV-2 fusion machinery core | ||
| − | | | + | |https://www.biorxiv.org/content/10.1101/2021.05.24.445443v2/ |
|3 | |3 | ||
|- | |- | ||
|110 | |110 | ||
|Revealing the spike's real shape | |Revealing the spike's real shape | ||
| − | | | + | |https://www.science.org/content/blog-post/revealing-spike-s-real-shape/ |
|3 | |3 | ||
|- | |- | ||
|113 | |113 | ||
|SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes | |SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes | ||
| − | | | + | |https://www.nature.com/articles/s41467-021-22905-7?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_NRJournals/ |
|3 | |3 | ||
|- | |- | ||
|116 | |116 | ||
|X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease | |X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abf7945/ |
|3 | |3 | ||
|- | |- | ||
|118 | |118 | ||
|Viral genomes reveal patterns of the SARS-CoV-2 outbreak in Washington State | |Viral genomes reveal patterns of the SARS-CoV-2 outbreak in Washington State | ||
| − | | | + | |https://www.science.org/doi/10.1126/scitranslmed.abf0202/ |
|3 | |3 | ||
|- | |- | ||
|120 | |120 | ||
|COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets | |COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-03570-8?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|3 | |3 | ||
|- | |- | ||
|125 | |125 | ||
|Structural biology in the time of COVID-19: perspectives on methods and milestones | |Structural biology in the time of COVID-19: perspectives on methods and milestones | ||
| − | | | + | |https://journals.iucr.org/m/issues/2021/03/00/mf5052/index.html/ |
|3 | |3 | ||
|- | |- | ||
|127 | |127 | ||
|Massively Multiplexed Affinity Characterization of Therapeutic Antibodies Against SARS-CoV-2 Variants | |Massively Multiplexed Affinity Characterization of Therapeutic Antibodies Against SARS-CoV-2 Variants | ||
| − | | | + | |https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1/ |
|3 | |3 | ||
|- | |- | ||
|128 | |128 | ||
|Fine-tuning the Spike: Role of the nature and topology of the glycan shield in the structure and dynamics of the SARS-CoV-2 S | |Fine-tuning the Spike: Role of the nature and topology of the glycan shield in the structure and dynamics of the SARS-CoV-2 S | ||
| − | | | + | |https://www.biorxiv.org/content/10.1101/2021.04.01.438036v2/ |
|3 | |3 | ||
|- | |- | ||
|133 | |133 | ||
|Identification of lectin receptors for conserved SARS-CoV-2 glycosylation sites | |Identification of lectin receptors for conserved SARS-CoV-2 glycosylation sites | ||
| − | | | + | |https://www.biorxiv.org/content/10.1101/2021.04.01.438087v1/ |
|3 | |3 | ||
|- | |- | ||
|134 | |134 | ||
|Electrostatic interactions between the SARS-CoV-2 virus and a charged electret fibre | |Electrostatic interactions between the SARS-CoV-2 virus and a charged electret fibre | ||
| − | | | + | |https://pubs.rsc.org/en/content/articlelanding/2021/sm/d1sm00232e/ |
|3 | |3 | ||
|- | |- | ||
|144 | |144 | ||
|How SARS-CoV-2’s Sugar-Coated Shield Helps Activate the Virus | |How SARS-CoV-2’s Sugar-Coated Shield Helps Activate the Virus | ||
| − | | | + | |https://www.biophysics.org/news-room/how-sars-cov-2s-sugar-coated-shield-helps-activate-the-virus/ |
|3 | |3 | ||
|- | |- | ||
|147 | |147 | ||
|Structural basis for backtracking by the SARS-CoV-2 replication-transcription complex | |Structural basis for backtracking by the SARS-CoV-2 replication-transcription complex | ||
| − | | | + | |https://www.biorxiv.org/content/10.1101/2021.03.13.435256v1/ |
|3 | |3 | ||
|- | |- | ||
|155 | |155 | ||
|The emerging plasticity of SARS-CoV-2 | |The emerging plasticity of SARS-CoV-2 | ||
| − | | | + | |https://science.sciencemag.org/content/371/6536/1306.full/ |
|3 | |3 | ||
|- | |- | ||
|157 | |157 | ||
|Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 | |Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 | ||
| − | | | + | |https://science.sciencemag.org/content/371/6531/850/ |
|3 | |3 | ||
|- | |- | ||
|3 | |3 | ||
|Identification of lection receptor for conserved SARS-C0V-2 glycosilation | |Identification of lection receptor for conserved SARS-C0V-2 glycosilation | ||
| − | | | + | |https://www.biorxiv.org/content/10.1101/2021.04.01.438087v1/ |
|3 | |3 | ||
|- | |- | ||
|5 | |5 | ||
|Computational epitope map of SARS-CoV-2 spike protein | |Computational epitope map of SARS-CoV-2 spike protein | ||
| − | | | + | |https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1008790/ |
|3 | |3 | ||
|- | |- | ||
|8 | |8 | ||
|Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron | |Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron | ||
| − | | | + | |https://www.nature.com/articles/s41586-022-04399-5#Echobox=1641674359/ |
|4 | |4 | ||
|- | |- | ||
|13 | |13 | ||
|Structural basis of Omicron neutralization by affinity-matured public antibodies | |Structural basis of Omicron neutralization by affinity-matured public antibodies | ||
| − | | | + | |https://www.biorxiv.org/content/10.1101/2022.01.03.474825v1/ |
|4 | |4 | ||
|- | |- | ||
|18 | |18 | ||
|The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism | |The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism | ||
| − | | | + | |https://www.gla.ac.uk/media/Media_829360_smxx.pdf/ |
|4 | |4 | ||
|- | |- | ||
|20 | |20 | ||
|Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant | |Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abl9551?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|4 | |4 | ||
|- | |- | ||
|23 | |23 | ||
|CryoEM structure of Omicron (B.1.1.529) variant spike protein in complex with human ACE2 reveals new salt bridges formed by mutated residues R498 and R493 in the RBD and residues D38 and E35, respectively, in ACE2. | |CryoEM structure of Omicron (B.1.1.529) variant spike protein in complex with human ACE2 reveals new salt bridges formed by mutated residues R498 and R493 in the RBD and residues D38 and E35, respectively, in ACE2. | ||
| − | | | + | |https://twitter.com/cryoem_UBC/status/1471390036851511299/ |
|4 | |4 | ||
|- | |- | ||
|27 | |27 | ||
|SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals | |SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals | ||
| − | | | + | |https://www.medrxiv.org/content/10.1101/2021.12.08.21267491v1/ |
|4 | |4 | ||
|- | |- | ||
|28 | |28 | ||
|Modelling the potential consequences of the Omicron SARS-CoV-2 variant in England | |Modelling the potential consequences of the Omicron SARS-CoV-2 variant in England | ||
| − | | | + | |https://cmmid.github.io/topics/covid19/omicron-england.html/ |
|4 | |4 | ||
|- | |- | ||
|29 | |29 | ||
|Omicron and Delta Variant of SARS-CoV-2: A Comparative Computational Study of Spike protein | |Omicron and Delta Variant of SARS-CoV-2: A Comparative Computational Study of Spike protein | ||
| − | | | + | |https://www.biorxiv.org/content/10.1101/2021.12.02.470946v1/ |
|4 | |4 | ||
|- | |- | ||
|30 | |30 | ||
|Where did ‘weird’ Omicron come from? | |Where did ‘weird’ Omicron come from? | ||
| − | | | + | |https://www.science.org/content/article/where-did-weird-omicron-come?utm_campaign=NewsfromScience&utm_source=Social&utm_medium=Twitter/ |
|4 | |4 | ||
|- | |- | ||
|31 | |31 | ||
|The Omicron SARSCoV2 mutations in each gene and the drugs, candidates, & vaccines that target them. The 3CL protease and RNA polymerase have only 1 mutation each (unlike spike, which has >30); the drug candidates targeting them might be more likely to retain efficacy. | |The Omicron SARSCoV2 mutations in each gene and the drugs, candidates, & vaccines that target them. The 3CL protease and RNA polymerase have only 1 mutation each (unlike spike, which has >30); the drug candidates targeting them might be more likely to retain efficacy. | ||
| − | | | + | |https://twitter.com/davidrliu/status/1464714206150807559/photo/1/ |
|4 | |4 | ||
|- | |- | ||
|38 | |38 | ||
|The mutation map of the 5 Variants of Concern | |The mutation map of the 5 Variants of Concern | ||
| − | | | + | |https://covariants.org/shared-mutations/ |
|4 | |4 | ||
|- | |- | ||
|55 | |55 | ||
|Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern | |Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern | ||
| − | | | + | |https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern/ |
|4 | |4 | ||
|- | |- | ||
|60 | |60 | ||
|Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants | |Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abl8506?utm_campaign=SciMag&utm_source=Social&utm_medium=Twitter/ |
|4 | |4 | ||
|- | |- | ||
|68 | |68 | ||
|The mutation that helps Delta spread like wildfire | |The mutation that helps Delta spread like wildfire | ||
| − | | | + | |https://www.nature.com/articles/d41586-021-02275-2?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|4 | |4 | ||
|- | |- | ||
|77 | |77 | ||
|SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern | |SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abi7994/ |
|4 | |4 | ||
|- | |- | ||
|97 | |97 | ||
|Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence | |Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence | ||
| − | | | + | |https://www.science.org/doi/full/10.1126/science.abj0113/ |
|4 | |4 | ||
|- | |- | ||
|111 | |111 | ||
|Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization | |Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-03777-9?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|4 | |4 | ||
|- | |- | ||
|122 | |122 | ||
|Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets | |Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abi5224/ |
|4 | |4 | ||
|- | |- | ||
|130 | |130 | ||
|Coronavirus variants are spreading in India — what scientists know so far | |Coronavirus variants are spreading in India — what scientists know so far | ||
| − | | | + | |https://www.nature.com/articles/d41586-021-01274-7?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NGMT_USG_JC01_GL_Nature/ |
|4 | |4 | ||
|- | |- | ||
|150 | |150 | ||
|Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil | |Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil | ||
| − | | | + | |https://www.science.org/doi/10.1126/science.abh2644/ |
|4 | |4 | ||
|- | |- | ||
|154 | |154 | ||
|A novel variant of interest of SARS-CoV-2 with multiple spike mutations detected through travel surveillance in Africa | |A novel variant of interest of SARS-CoV-2 with multiple spike mutations detected through travel surveillance in Africa | ||
| − | | | + | |https://www.krisp.org.za/publications.php?pubid=330/ |
|4 | |4 | ||
|- | |- | ||
|158 | |158 | ||
|Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 | |Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 | ||
| − | | | + | |https://www.nature.com/articles/s41586-021-03398-2/ |
|4 | |4 | ||
|- | |- | ||
|159 | |159 | ||
|Development of potency, breadth and resilience to viral escape mutation in SARS-CoV-2 neutralizing anitbodies | |Development of potency, breadth and resilience to viral escape mutation in SARS-CoV-2 neutralizing anitbodies | ||
| − | | | + | |https://www.biorxiv.org/content/10.1101/2021.03.07.434227v1/ |
|4 | |4 | ||
|- | |- | ||
|160 | |160 | ||
| − | | | + | |SARS-CoV-2 Variants | UK+ South African + Brazil Variants/ |
| − | | | + | |https://www.youtube.com/watch?v=OYgVmOLF2mY/ |
|4 | |4 | ||
|- | |- | ||
|162 | |162 | ||
|Summary of Clinical Data on New Coronavirus Variant, Suggests Humans can still win the Long war | |Summary of Clinical Data on New Coronavirus Variant, Suggests Humans can still win the Long war | ||
| − | | | + | |https://m.weibo.cn/status/4647414625212687?sourceType=weixin&from=10AC195010&wm=4260_0001&featurecode=newtitle/ |
|4 | |4 | ||
|- | |- | ||
|163 | |163 | ||
| − | |Delta Variant US confirmed | + | |Delta Variant US confirmed rate doubles in 7 days! |
| − | | | + | |https://mp.weixin.qq.com/s/8lRnwUUz_3dV7QMtfg2s4w/ |
|4 | |4 | ||
|- | |- | ||
|164 | |164 | ||
|Delta variant isn’t over, Delta+ variant strikes again | |Delta variant isn’t over, Delta+ variant strikes again | ||
| − | | | + | |https://m.weibo.cn/status/4650675290506335?sourceType=weixin&from=10B6195010&wm=2468_1001&featurecode=newtitle/ |
|4 | |4 | ||
|- | |- | ||
|165 | |165 | ||
|Delta coronavirus variant: scientists brace for impact | |Delta coronavirus variant: scientists brace for impact | ||
| − | | | + | |https://www.nature.com/articles/d41586-021-01696-3?utm_source=twt_nat&utm_medium=social&utm_campaign=nature/ |
|4 | |4 | ||
|- | |- | ||
|166 | |166 | ||
|Menacing: What is the new crown Delta mutant, and how can we respond? | |Menacing: What is the new crown Delta mutant, and how can we respond? | ||
| − | | | + | |https://mp.weixin.qq.com/s/g9gPLEN6R02F49eRGGSuAA/ |
|4 | |4 | ||
|- | |- | ||
|167 | |167 | ||
|Race to understand Sars-CoV-2 variants amid fears virus might evade vaccines | |Race to understand Sars-CoV-2 variants amid fears virus might evade vaccines | ||
| − | | | + | |https://www.chemistryworld.com/news/race-to-understand-sars-cov-2-variants-amid-fears-virus-might-evade-vaccines/4013891.article/ |
|4 | |4 | ||
|} | |} | ||
Revision as of 19:22, 11 February 2022
SARS-CoV-2 Article Collection